Immunothérapie et cancer du poumon : où en sommes-nous ?

Lung cancer is one of the deadliest cancers but also benefits from the greatest therapeutic advances. Genotype-directed lung cancer care has led to dramatic improvement in the management of patients harboring a targetable oncogenic driver but only concerns a limited number of patients. After decades of disappointments with antitumor immunotherapy, the tide has finally change due to the recent positive results from clinical trials evaluating immune checkpoint inhibitors. These new drugs are already the new standard of care after failure of chemo but also frontline for patients with strong PD-L1 expression or in combination with chemo. However, further basic, translational and clinical research is needed to better select the limited proportion of patients that will derive a benefit from these drugs and guide combination therapies in others (immune checkpoints inhibitors combinations, associations with vaccines, targeted therapies or chemotherapies).